The Plastic Health Research Act amends the Public Health Service Act to create a coordinated federal research program on plastic exposures and their potential health effects. It directs the HHS Secretary to work with EPA, FDA, NOAA, NIST, and NIEHS to expand and prioritize research that produces reproducible methods, validated testing, and standard definitions for microplastics and nanoplastics.
The bill authorizes two complementary funding streams: competitive grants and contracts for individual research projects and 5‑year centers of excellence that receive basic operating support. Both streams emphasize method development, reference materials, exposure and hazard assessment, and public‑facing reporting; each is authorized at $10 million per year for FY2026–2030.
At a Glance
What It Does
The bill requires the HHS Secretary, in consultation with EPA, FDA, NOAA, NIST, and NIEHS, to expand and coordinate research on plastic exposures, prioritize development of vetted methods and reference materials, award grants and contracts to eligible entities, and establish centers of excellence. It mandates annual public reports for five years and prescribes information sharing among listed agencies.
Who It Affects
Academic and nonprofit researchers, public health institutes, testing laboratories, and consortia (including those that collaborate with private firms) are eligible for funding; HHS and the named federal agencies must coordinate and absorb administrative duties; labs and standards bodies (e.g., NIST) will play a central role in producing reference materials.
Why It Matters
The bill focuses federal effort on measurability and comparability—standard definitions, validated assays, and reference materials—which are prerequisites for credible risk assessment and any downstream regulatory or clinical guidance. It establishes durable institutional structures (centers) rather than one‑off grants, signaling an intent to build research infrastructure for plastic exposure science.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
This bill instructs the Department of Health and Human Services to expand federal research into human exposure to plastics — including macroplastics, microplastics, and nanoplastics — and the possible health effects of those exposures. HHS must consult a defined set of agencies (EPA, FDA, NOAA, NIST, and NIEHS) and prioritize projects that produce reproducible research methods, standardized material definitions, validated testing approaches, and reference materials that labs can use to compare results across studies.
One path the bill creates is competitive grants and contracts to public entities, nonprofits, academic institutions, and consortia (consortia may partner with private entities). Awarded projects must advance method quality and comparability or fill identified gaps in health effects research.
Recipients will be subject to application requirements set by HHS, and the Secretary must produce an initial public report one year after enactment and then annually for four more years summarizing supported research and findings.The bill also creates centers of excellence to provide sustained, multi‑year capacity: grants or funding agreements support planning, establishment, and basic operations for centers that prioritize method development, exposure assessment, hazard and risk assessment, and public awareness activities where warranted. Center awards last five years and are renewable for additional five‑year terms contingent on peer review recommendations.
HHS must share findings broadly with the named agencies and release annual center research overviews for five years.Both the grant stream and the centers stream explicitly authorize appropriations of $10 million per year for fiscal years 2026 through 2030. The statutory definition of “plastic exposure” is broad and includes production, occupational and environmental exposure, end‑user contact (e.g., food packaging, textiles), recycling, degradation, and disposal — a scope that pushes research from purely environmental monitoring toward lifecycle and occupational questions as well.
The Five Things You Need to Know
The bill authorizes competitive grants and contracts for plastic exposure research and prioritizes projects that produce vetted, reproducible methods, standard definitions, and validated testing approaches.
HHS must consult EPA, FDA, NOAA, NIST, and NIEHS when carrying out, expanding, and coordinating research activities and share funded research findings with those agencies.
Centers of excellence receive 5‑year grants (renewable for additional 5‑year periods after peer review) to develop reference materials, exposure assessment methodologies, and risk/hazard assessment tools.
Both the grant program (section 399V–8) and the centers program (section 463C) are separately authorized at $10 million per year for each program for FY2026–2030.
The statute defines 'plastic exposure' broadly to include macroplastics, microplastics, and nanoplastics across production, occupational settings, consumer handling (food packaging, textiles), recycling, degradation, and waste/disposal pathways.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — 'Plastic Health Research Act'
A single line provides the public name of the act. This is procedural but important because the rest of the bill references this short title in administrative materials and outreach.
HHS coordination, research priorities, and grant authority
This new PHSA section requires the HHS Secretary to lead a coordinated research program on plastic exposure health effects and to consult five named agencies. It sets explicit research priorities: develop vetted, reproducible research methods; create standard material definitions for micro‑ and nanoplastics; and develop validated testing methodologies and reference materials across media. The Secretary may award grants and contracts to public, nonprofit, academic entities and consortia (including those that work with private firms). Administrative mechanics include application requirements determined by the Secretary, mandated public reporting starting one year after enactment and annually for four subsequent years, interagency information sharing, and a $10M/year authorization for FY2026–2030 for this subsection.
Broad statutory definition of 'plastic exposure'
The provision defines plastic exposure to include macroplastics, microplastics, and nanoplastics and lists exposure contexts: production, occupational, environmental, consumer handling, recycling, degradation, and waste/disposal. Practically, this broad definition expands eligible research topics and data collection beyond environmental monitoring to life‑cycle and occupational studies, affecting study design and required expertise.
Centers of excellence: purpose, eligible uses, and grant structure
Section 463C authorizes HHS (through the Institute Director) to fund centers that plan, establish, strengthen, and operate research hubs focused on improving scientific quality and informing public health determinations. Allowable uses include development of hazard/exposure/risk assessment methodologies, comprehensive chemical and physical characterization of plastics, validated testing across media, QA/QC practices, and public awareness where scientifically warranted. Grants are for five years, renewable after peer review, enabling longer‑term institutional capacity building rather than short project funding.
Mandatory interagency coordination and public reporting
Both the grants program and the centers program require coordination with the same set of agencies and mandate that research findings be shared with those agencies. Each program also requires an initial public report one year after enactment and annual reports for four subsequent years. This creates multiple formal information flows intended to accelerate translation of research outputs to agencies responsible for standards, environmental regulation, and public health guidance.
Funding floors and applicant rules
The bill sets explicit authorizations of $10 million per year for each program for FY2026–2030 (i.e., separate authorizations for the grants stream and the centers stream). Eligibility is broad — public entities, nonprofits, academic institutions, or consortia — and the bill allows consortia to collaborate with private entities, which affects intellectual property, data sharing, and conflict‑of‑interest considerations that HHS will need to address in application rules.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Academic research institutions: Receive targeted funding to build capacity, develop standard methods, and secure long‑term center support that can sustain multi‑disciplinary studies across exposure pathways.
- Standards and testing labs (including NIST collaborators): Gain federal backing to develop reference materials and validated assays, which can professionalize and commercialize measurement services.
- Public health agencies and practitioners: Get systematic, comparable data and hazard/risk assessment tools that make surveillance and health guidance more defensible and actionable.
- Communities with occupational or high environmental exposure: Stand to benefit indirectly as improved exposure assessment and risk characterization can inform mitigation strategies and workplace protections.
Who Bears the Cost
- Department of Health and Human Services and participating federal agencies: Must allocate staff time and administrative resources to coordinate programs, manage grants/centers, review applications, and produce required reports.
- Testing laboratories and academic cores: Will likely need to invest in new equipment, QA/QC procedures, and personnel to implement validated methodologies and produce reference materials.
- Taxpayers/federal budget: The bill authorizes $20 million per year total across the two programs for five fiscal years, creating a recurring appropriations demand that Congress must fund.
- Private sector consortia partners: If participating with funded consortia, private firms may be asked to share data, adhere to public disclosure commitments, or accept intellectual‑property terms that reduce commercial exclusivity.
Key Issues
The Core Tension
The bill tries to solve a credibility problem (inconsistent measurements and methods) by privileging standardization and centralized research, but doing so with limited funding and without detailed governance rules risks either entrenching an early consensus that blocks better methods or failing to build sufficiently robust infrastructure to produce regulatory‑grade evidence; the choice is between rapid comparability and careful, possibly slower, methodological evolution.
Two practical constraints shape how much this bill can change the science: funding scale and methodological complexity. The authorized amounts—$10 million per year for each program—are meaningful for targeted projects or a few centers but modest relative to the multi‑disciplinary investments typically required to establish national reference systems, interlaboratory networks, and large longitudinal exposure cohorts.
Translating validated methods and reference materials into routine surveillance and clinical practice will likely require additional, sustained funding beyond FY2030.
The bill deliberately opens funding to consortia that may include private entities and mandates public reporting and interagency sharing of findings. That creates a tension between collaborative research that leverages industry capabilities (material supply chains, manufacturing data) and the need to manage conflicts of interest, data access, and intellectual property.
The statute leaves many implementation details—application conditions, data‑sharing rules, conflict‑of‑interest safeguards, and whether HHS will require open data or permit proprietary methods—to agency policy, so the real effect on transparency and industry participation will depend on those forthcoming rules.
Finally, the statute emphasizes standardization and reproducibility, which is appropriate given current variability in methods. But establishing common definitions and validated assays risks premature consolidation around imperfect techniques.
If HHS or the centers favor a specific standard too early, it could slow methodological innovation or lock in measures that later prove suboptimal for certain exposure routes (e.g., inhalation vs ingestion) or particle classes (macro vs nano).
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.